Myocardial infarction Circulatory System Myocardial infarction
Conditions
Interventions
Following provision of informed consent, all participants have a blood sample taken which is immediately frozen for the future primary outcome analysis. Peripheral blood samples are drawn into n°3 BD
Sponsors
Università degli Studi di Pavia
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Cases: 1. Age between 18 and 75 years, inclusive 2. At least one episode of cardiac arrest due to ventricular fibrillation within 24 h of onset of symptoms of heart attack documented in the index electrocardiogram Controls: 1. Age between 18 and 75 years, inclusive 2. Episode of myocardial infarction within 24 h of onset of symptoms
Exclusion criteria
Exclusion criteria: Case Patients Exclusion criteria: 1. Age younger than 18 or older than 75 years 2. History of previous myocardial infarction 3. Pre-existing significant cardiac disease and / or associated with Ejection Fraction less than or equal to 30% 4. Presence of arrhythmogenic diseases that affect the occurrence of major ventricular arrhythmias (TV, FV) independently by the ischemic event (arrhythmogenic right end/or left ventricular cardiomiopathies, long- and short-QT syndrome; Brugada syndrome and Cathecolaminergic polymorphic ventricular tachicardia) Control Patients Exclusion criteria: 1. Age younger than 18 or older than 75 years 2. History of previous myocardial infarction 3. Pre-existing significant cardiac disease and / or associated with Ejection Fraction less than or equal to 30% 4. Presence of arrhythmogenic diseases that affect the occurrence of major ventricular arrhythmias (TV, FV) independently by the ischemic event (arrhythmogenic right end/or left ventricular cardiomiopathies, long- and short-QT syndrome; Brugada syndrome and Cathecolaminergic polymorphic ventricular tachicardia)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Genetic loci associated with ventricular fibrillation risk during myocardial infarction are assessed through analysis of 1,536 SNPs (single nucleotide polymorphisms) using the GoldenGate method (Illumina) with a custom-made chip and the Genome Wide Association Study (GWAS) technique at 1 year. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Relationship between the occurrence of ventricular fibrillation and 1.1. familiarity for sudden death 1.2. Smoking habit 1.3. Hypokalemia 1.4. Hyperkalemia 1.5. Prolonged corrected QT interval is assessed using information collected using case reports collected at baseline 2. Survival status is assessed through medical record review at one year | — |
Countries
Italy
Outcome results
None listed